Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Survey Finds Slight Increase in Generic Drug Dispensing Rate
October 21, 2011
- MHLW to Review Premium System Placing Priority on Premium for Pediatric Use
October 20, 2011
- Mr Kobayashi of Chuikyo Insists on NHI Price Reductions for New Generics
October 20, 2011
- MHLW Subcommittee Agrees on Access System for Domestically Unapproved Drugs
October 20, 2011
- MHLW Presents Data at Chuikyo Supporting Reduction in 70% Rule for New Generics
October 20, 2011
- Cost of Advanced Healthcare Services Totaled ¥13.2 Billion in FY2010: Korosho
October 20, 2011
- HSC Subcommittee Considering Review of Refractory Diseases Eligible for Treatment Subsidies
October 20, 2011
- MHLW Revises Precautions for Use in OTC Drugs
October 19, 2011
- PMDA Presents Warnings on Website to Prevent Mistaken Use of 3 Taxane Drugs
October 19, 2011
- Korosho Proposes 80% Price Rule for Single-enantiomer Drugs
October 19, 2011
- Korosho Presents Direction for PAL Amendment in 2012
October 19, 2011
- Council to Set Up Committee to Discuss Creation of “Drug Discovery Support Organization”
October 18, 2011
- MHLW to Survey, Consider Measures for Clinical Trials in Coping with Earthquakes
October 17, 2011
- Health Minister Shows Positive Attitude Towards Participation in TPP Talks
October 17, 2011
- Vice Minister Tsuji Supports Continuation of Premium for New Drug Development
October 17, 2011
- Korosho Task Force Discusses Upcoming Switch to Inactivated Polio Vaccine
October 17, 2011
- Avastin Approved for Treatment of Breast Cancer in Combination with Paclitaxel
October 13, 2011
- Revision of Ryotan-kisoku to Be Considered to Control Dispensing Point Services
October 13, 2011
- Chuikyo to Discuss “Dispensing Points” Offered by Pharmacies
October 12, 2011
- Drug Expenditure Higher than Apparent Due to Hidden Drug Expenditure: Korosho
October 12, 2011
ページ
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…